☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
OncoSec
OncoSec Reports P-II Trial (KEYNOTE-695) of TAVO-EP + Keytruda (pembrolizumab) for Advanced Melanoma
April 4, 2023
OncoSec Reports P-II (KEYNOTE-695) Trial Results of TAVO-EP + Keytruda (pembrolizumab) for Advanced Melanoma
November 14, 2022
Load more...
Back to Home
Modal title
×
Modal body text goes here.
